Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1225

Sort by

Sort Order Select

Journal Articles

YWHAE/14-3-3ε expression impacts the protein load, contributing to proteasome inhibitor sensitivity in multiple myeloma

Blood (2020) 136 (4): 468–479.

https://doi.org/10.1182/blood.2019004147

Published: 2020

Includes: Supplemental data

Journal Articles

GPS2 promotes erythroid differentiation by control of the stability of EKLF protein

Wen-Bing Ma, Xiao-Han Wang, Chang-Yan Li, Huan-Huan Tian, Jie Zhang, Jun-Jie Bi, Guang-Ming Ren, Shou-Song Tao, Xian Liu, Wen Zhang, Dong-Xu Li, Hui Chen, Yi-Qun Zhan, Miao Yu, Chang-Hui Ge, Xiao-Ming Yang, Rong-Hua Yin

Blood (2020) 135 (25): 2302–2315.

https://doi.org/10.1182/blood.2019003867

Published: 2020

Includes: Supplemental data

Journal Articles

A master erythroid regulator gets its own GPS

Lily Jun-shen Huang, James J. Bieker

Blood (2020) 135 (25): 2209–2210.

https://doi.org/10.1182/blood.2020005882

Published: 2020

Journal Articles

A Comprehensive Analysis of Single-Cell Chromatin Accessibility and Gene Expression Identifies Intra-Tumor Heterogeneity and Molecular Treatment Responses in Relapsed/Refractory Multiple Myeloma

Blood (2019) 134 (Supplement_1): 575.

https://doi.org/10.1182/blood-2019-130051

Published: 2019

Journal Articles

Identification of Thrombospondin-1 As a Novel Substrate of Cereblon Responsible for IMiDs-Induced Venous Thromboembolism

Kiwamu Hatakeyama, MD, Yoshikane Kikushige, MD PhD, Toshihiro Miyamoto, MD PhD, Koichi Akashi, MD PhD

Blood (2019) 134 (Supplement_1): 631.

https://doi.org/10.1182/blood-2019-125670

Published: 2019

Journal Articles

Selective Dependency of MLL-Rearranged Leukemia on Immunoproteasome Function

Nuria Tubío Santamaría, Jonas Tönsing, Tina M. Schnoeder, PhD, Ulrike Seifert, Clemens Cammann, Juliane Mohr, PhD, Aniruddha J. Deshpande, PhD, Joanna Kirkpatrick, Alessandro Ori, PhD, Florian Perner, MD, Florian H. Heidel, MD

Blood (2019) 134 (Supplement_1): 529.

https://doi.org/10.1182/blood-2019-122100

Published: 2019

Journal Articles

Regulation of Erythroid Heme Synthesis By the Mitochondrial Clpx Unfoldase

Catherine Rondelli, Aiden Danoff, Hector Bergonia, Samantha Gillis, Julia Free, John D. Phillips, PhD, Yvette Y Yien, PhD

Blood (2019) 134 (Supplement_1): 427.

https://doi.org/10.1182/blood-2019-132039

Published: 2019

Journal Articles

A Phase 1 Study of Carfilzomib-Thalidomide-Dexamethasone in Patients with Relapsed/Refractory AL Amyloidosis - Catalyst Trial Results

Mamta Garg, MD FRCP, FRCPath, Andrew Hall, Matthew Jenner, MBBS, MRCP, FRCPath, Bhuvan Kishore, MB BS, MRCP, FRCPath, Helen J Lachmann, MA MB BChir MDFRCP, Julian D Gillmore, MBBS, MD PhD FRCP, Alexandra Pitchford, Louise Flanagan, PhD, Jamie B Oughton, MPhil, BSc, Shameem Mahmood, Sajitha Sachchithanantham, Sarah R Brown, PhD MSc, BSc, Ashutosh D Wechalekar, MBBS, MD FRCP, FRCPath, DM

Blood (2019) 134 (Supplement_1): 1890.

https://doi.org/10.1182/blood-2019-126567

Published: 2019

Journal Articles

RNA-Sequencing Based Assessment of Targets, Risk and Long Term Survival for Personalized Treatment of Multiple Myeloma

Martina Emde, Susanne Beck, Vladimir Benes, Jerome Moreaux, PhD, Anja Seckinger, Dirk Hose, MD

Blood (2019) 134 (Supplement_1): 1801.

https://doi.org/10.1182/blood-2019-131159

Published: 2019

Journal Articles

TNF-α Confers Resistance of Myeloma Cells to IMiDs through TRAF2 Degradation

Jiye Liu, PhD, Teru Hideshima, MD PhD, Lijie Xing, MD, Kenneth Wen, BS, Yu-Tzu Tai, PhD, Yong Cang, PhD, Kenneth C. Anderson, MD

Blood (2019) 134 (Supplement_1): 1809.

https://doi.org/10.1182/blood-2019-123141

Published: 2019

Journal Articles

Overexpression of MPL Causes Ruxolitinib-Resistance in Myeloproliferative Neoplasms with Calreticulin Frame-Shift Mutations

Shunichiro Yasuda, MD, Satoru Aoyama, MD, Ryoto Yoshimoto, Student, Watanabe Daisuke, MD, Hiroki Akiyama, MD, PhD, Yoshihiro Umezawa, MD, PhD, Ayako Nogami, MD PhD BPharm, Kouhei Yamamoto, Takeo Fujiwara, MD, Yoko Edahiro, MD PhD, Marito Araki, PhD, Norio Komatsu, MD PhD, Tetsuya Fukuda, MD PhD, Ayako Arai, MD PhD, Osamu Miura, MD, PhD, Norihiko Kawamata

Blood (2019) 134 (Supplement_1): 1690.

https://doi.org/10.1182/blood-2019-122652

Published: 2019

Journal Articles

Profiling the Cell Surface Landscape of Proteasome Inhibitor-Treated and -Resistant Multiple Myeloma to Guide Immunotherapy Targeting, Diagnosis, and Biology

Ian Ferguson, BA, Yu-Hsiu T. Lin, BA, Sami Tuomivaara, PhD, Jeffrey L. Wolf, MD, Thomas G. Martin, III, MD, Sandy W. Wong, MD, Nina D. Shah, MD, Christoph Driessen, MD, Brian G. Van Ness, PhD, Arun P. Wiita, MD PhD

Blood (2019) 134 (Supplement_1): 1803.

https://doi.org/10.1182/blood-2019-131681

Published: 2019

Journal Articles

Multidimensional Single Cell Analysis Shows Increased T/NK Cell Subsets in Both Blood and Bone Marrow of Iberdomide (CC-220) Treated Relapsed/Refractory Multiple Myeloma Patients

Michael Amatangelo, Oliver Van Oekelen, MD MSc, Adeeb H Rahman, PhD, Alessandro Lagana, PhD, Sarah Gooding, FRCPath,MRCP,MBBChir, Hervé Avet-Loiseau, MD PhD, Udo Oppermann, PhD, William E Pierceall, PhD, Anjan Thakurta, Samir Parekh, MD

Blood (2019) 134 (Supplement_1): 1775.

https://doi.org/10.1182/blood-2019-126146

Published: 2019

Journal Articles

Integrated Systems Level Examination of Proteasome Inhibitor Stress Recovery in Myeloma Cells Reveals Druggable Vulnerabilities Linked to Multiple Metabolic Processes

Paula Saavedra-Garcia, PhD, Hibah A Al-Sadah, MSc, Lucy Penfold, PhD, Xiaobei Xiong, MRes, Elena Lopez-Jimenez, PhD, Katarzyna Parzych, PhD, Valentina S Caputo, Kevin Blighe, PhD, Martin F. Kaiser, Paolo Piazza, PhD, Vesela Encheva, PhD, Ambrosius P Snijders, PhD, Hector C Keun, DPhil, Diego Oyarzun, PhD, Denise Thiel, MSc, Zijing Liu, PhD, Mauricio Barahona, PhD, Holger W Auner, MD PhD

Blood (2019) 134 (Supplement_1): 1818.

https://doi.org/10.1182/blood-2019-121549

Published: 2019

Journal Articles

Hexokinase-2 Regulates Hypoxia-Inducible Autophagy, Leading to Enhance Anti-Apoptotic Capability of Refractory Multiple Myeloma

Sho Ikeda, MD PhD, Fumito Abe, MD PhD, Matsuda Yuka, Akihiro Kitadate, MD PhD, Takahiro Kobayashi, MD PhD, Naoto Takahashi, MD PhD, Hiroyuki Tagawa, MD PhD

Blood (2019) 134 (Supplement_1): 1787.

https://doi.org/10.1182/blood-2019-123360

Published: 2019

Journal Articles

Efficacy and Safety of Nivolumab Combined with Daratumumab with or without Low-Dose Cyclophosphamide in Relapsed/Refractory Multiple Myeloma; Interim Analysis of the Phase 2 Nivo-Dara Study

Christie P.M. Verkleij, MD, Monique C. Minnema, Okke de Weerdt, MD, Patricia W.C. Bosman, MSc, Kristine A. Frerichs, MD, Alexandra J. Croockewit, MD PhD, Saskia K. Klein, MD PhD, Gerard Bos, MD PhD, Tuna Mutis, Wouter J. Plattel, MD, Ellen van der Spek, MD PhD, Annemiek Broyl, MD PhD, Pieter Sonneveld, Sonja Zweegman, MD PhD, Mark-David Levin, MD PhD, Niels W. C. J. Van De Donk, MD PhD

Blood (2019) 134 (Supplement_1): 1879.

https://doi.org/10.1182/blood-2019-124339

Published: 2019

Journal Articles

CC-92480, a Novel Cereblon E3 Ligase Modulator, Is Synergistic with Dexamethasone, Bortezomib, and Daratumumab in Multiple Myeloma

Lilly Wong, Rama Krishna Narla, Jim Leisten, Daniel Bauer, Matthew Groza, Bonny Gaffney, Courtney G. Havens, Justin Choi, Jack Houston, Antonia Lopez-Girona, Joshua Hansen, Brian E. Cathers, James Carmichael, Daniel W. Pierce

Blood (2019) 134 (Supplement_1): 1815.

https://doi.org/10.1182/blood-2019-124345

Published: 2019

Journal Articles

Use of Maintenance Therapy Post Autologous Stem Cell Transplantation Outside of Clinical Trial Setting for Multiple Myeloma: Single Institution Experience

Dhauna Karam, MD, Morie A Gertz, MD, Martha Q. Lacy, MD, Angela Dispenzieri, MD, Suzanne R. Hayman, MD, David Dingli, MD PhD, Prashant Kapoor, MD, Taxiarchis Kourelis, MD, Rahma M Warsame, MD, William J Hogan, MB, BCh, Shaji K. Kumar, MD

Blood (2019) 134 (Supplement_1): 2013.

https://doi.org/10.1182/blood-2019-128345

Published: 2019

Journal Articles

Retrospective Review of Appropriate Use of Antimicrobials and Anticoagulants in Patients Hospitalized for a Malignant Hematologic Condition

Louis-Bassett Porter, MD, Hanaa Shihadeh, Kim Dittus, MD PhD

Blood (2019) 134 (Supplement_1): 2116.

https://doi.org/10.1182/blood-2019-121534

Published: 2019

Journal Articles

Machine Learning Unveils Proteotypic Mimicry in Genetically Defined SCN Variants

Sebastian Hesse, MD, Christoph Klein, MD PhD, Rappsilber Juri, Prof., Yoko Mizoguchi, Monika Linder, PhD, Piotr Grabowski, PhD, Zahra Alizadeh, PhD, Zahra Pourpak, MD PhD, Nima Rezaei, MD PhD, Sorin Iurian, MD PhD, Ekrem Unal, MD, Fabian Hauck, MD PhD, Ralf Zimmer, Prof., Gergely Csaba, PhD

Blood (2019) 134 (Supplement_1): 3580.

https://doi.org/10.1182/blood-2019-131136

Published: 2019

NARROW

YWHAE/14-3-3ε expression impacts the protein load, contributing to proteasome inhibitor sensitivity in multiple myeloma

GPS2 promotes erythroid differentiation by control of the stability of EKLF protein

A master erythroid regulator gets its own GPS

A Comprehensive Analysis of Single-Cell Chromatin Accessibility and Gene Expression Identifies Intra-Tumor Heterogeneity and Molecular Treatment Responses in Relapsed/Refractory Multiple Myeloma

Identification of Thrombospondin-1 As a Novel Substrate of Cereblon Responsible for IMiDs-Induced Venous Thromboembolism

Selective Dependency of MLL-Rearranged Leukemia on Immunoproteasome Function

Regulation of Erythroid Heme Synthesis By the Mitochondrial Clpx Unfoldase

A Phase 1 Study of Carfilzomib-Thalidomide-Dexamethasone in Patients with Relapsed/Refractory AL Amyloidosis - Catalyst Trial Results

RNA-Sequencing Based Assessment of Targets, Risk and Long Term Survival for Personalized Treatment of Multiple Myeloma

TNF-α Confers Resistance of Myeloma Cells to IMiDs through TRAF2 Degradation

Overexpression of MPL Causes Ruxolitinib-Resistance in Myeloproliferative Neoplasms with Calreticulin Frame-Shift Mutations

Profiling the Cell Surface Landscape of Proteasome Inhibitor-Treated and -Resistant Multiple Myeloma to Guide Immunotherapy Targeting, Diagnosis, and Biology

Multidimensional Single Cell Analysis Shows Increased T/NK Cell Subsets in Both Blood and Bone Marrow of Iberdomide (CC-220) Treated Relapsed/Refractory Multiple Myeloma Patients

Integrated Systems Level Examination of Proteasome Inhibitor Stress Recovery in Myeloma Cells Reveals Druggable Vulnerabilities Linked to Multiple Metabolic Processes

Hexokinase-2 Regulates Hypoxia-Inducible Autophagy, Leading to Enhance Anti-Apoptotic Capability of Refractory Multiple Myeloma

Efficacy and Safety of Nivolumab Combined with Daratumumab with or without Low-Dose Cyclophosphamide in Relapsed/Refractory Multiple Myeloma; Interim Analysis of the Phase 2 Nivo-Dara Study

CC-92480, a Novel Cereblon E3 Ligase Modulator, Is Synergistic with Dexamethasone, Bortezomib, and Daratumumab in Multiple Myeloma

Use of Maintenance Therapy Post Autologous Stem Cell Transplantation Outside of Clinical Trial Setting for Multiple Myeloma: Single Institution Experience

Retrospective Review of Appropriate Use of Antimicrobials and Anticoagulants in Patients Hospitalized for a Malignant Hematologic Condition

Machine Learning Unveils Proteotypic Mimicry in Genetically Defined SCN Variants

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only